Tags

Type your tag names separated by a space and hit enter

Vaccination strategies to combat an infectious globe: oral cholera vaccines.
J Glob Infect Dis. 2011 Jan; 3(1):56-62.JG

Abstract

Cholera is a substantial health burden in many countries in Africa and Asia, where it is endemic. It is as well responsible for ongoing epidemics in sub-Saharan Africa which are becoming greater in terms of frequency, extension, and duration. Given the availability of two oral cholera vaccines and the new data on their efficacy, field effectiveness, feasibility, and acceptance in cholera-affected populations and in travelers, these vaccines should be used in endemic areas, in travelers for these areas and should be considered in areas at risk for outbreaks. The two vaccines currently available in worldwide are: (1) The killed oral vaccine (Dukoral, licensed by SBL-Sweden to Crucell-Holland) is recommended since 1999 by WHO and consists of a mixture of four preparations of heat or formalin killed whole cell Vibrio cholera O1 (Inaba and Ogaba serotypes, and classical and El Tor biotypes) that are then added with purified recombinant cholera toxin (CT) B subunit. Because CT cross-reacts with Escherichia coli LT the vaccine also provides short-term protection against ETEC (enterotoxigenic E. coli) which is of added benefit for travelers. It is available in more than 60 countries. (2) A bivalent O1 and O139 whole cell oral vaccine without CT B subunit (Shanchol) has been lately developed in Vietnam (licensed by VaBiotech-Viet Nam to Shantha Biotechnics-India. It is available in India and Indonesia. A structured search of papers in PubMed and reports on cholera vaccines by WHO and CDC, as well as critical reading and synthesis of the information was accomplished. Inclusion criteria were defined according to reports quality and relevance.

Authors+Show Affiliations

International Vaccination Centre of Malaga, Ministry of Health, Subdelegation in Malaga, Paseo Marítimo Pablo Ruiz, Picasso Malaga.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21572610

Citation

López-Gigosos, Rosa M., et al. "Vaccination Strategies to Combat an Infectious Globe: Oral Cholera Vaccines." Journal of Global Infectious Diseases, vol. 3, no. 1, 2011, pp. 56-62.
López-Gigosos RM, Plaza E, Díez-Díaz RM, et al. Vaccination strategies to combat an infectious globe: oral cholera vaccines. Journal of global infectious diseases. 2011;3(1):56-62.
López-Gigosos, R. M., Plaza, E., Díez-Díaz, R. M., & Calvo, M. J. (2011). Vaccination strategies to combat an infectious globe: oral cholera vaccines. Journal of Global Infectious Diseases, 3(1), 56-62. https://doi.org/10.4103/0974-777X.77297
López-Gigosos RM, et al. Vaccination Strategies to Combat an Infectious Globe: Oral Cholera Vaccines. Journal of global infectious diseases. 2011;3(1):56-62. PubMed PMID: 21572610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccination strategies to combat an infectious globe: oral cholera vaccines. AU - López-Gigosos,Rosa M, AU - Plaza,Elena, AU - Díez-Díaz,Rosa M, AU - Calvo,Maria J, PY - 2011/5/17/entrez PY - 2011/5/17/pubmed PY - 2011/5/17/medline KW - Cholera vaccines KW - Travelers KW - Vaccine-delivery strategies SP - 56 EP - 62 JF - Journal of global infectious diseases VL - 3 IS - 1 N2 - Cholera is a substantial health burden in many countries in Africa and Asia, where it is endemic. It is as well responsible for ongoing epidemics in sub-Saharan Africa which are becoming greater in terms of frequency, extension, and duration. Given the availability of two oral cholera vaccines and the new data on their efficacy, field effectiveness, feasibility, and acceptance in cholera-affected populations and in travelers, these vaccines should be used in endemic areas, in travelers for these areas and should be considered in areas at risk for outbreaks. The two vaccines currently available in worldwide are: (1) The killed oral vaccine (Dukoral, licensed by SBL-Sweden to Crucell-Holland) is recommended since 1999 by WHO and consists of a mixture of four preparations of heat or formalin killed whole cell Vibrio cholera O1 (Inaba and Ogaba serotypes, and classical and El Tor biotypes) that are then added with purified recombinant cholera toxin (CT) B subunit. Because CT cross-reacts with Escherichia coli LT the vaccine also provides short-term protection against ETEC (enterotoxigenic E. coli) which is of added benefit for travelers. It is available in more than 60 countries. (2) A bivalent O1 and O139 whole cell oral vaccine without CT B subunit (Shanchol) has been lately developed in Vietnam (licensed by VaBiotech-Viet Nam to Shantha Biotechnics-India. It is available in India and Indonesia. A structured search of papers in PubMed and reports on cholera vaccines by WHO and CDC, as well as critical reading and synthesis of the information was accomplished. Inclusion criteria were defined according to reports quality and relevance. SN - 0974-8245 UR - https://www.unboundmedicine.com/medline/citation/21572610/Vaccination_strategies_to_combat_an_infectious_globe:_oral_cholera_vaccines_ L2 - http://www.jgid.org/article.asp?issn=0974-777X;year=2011;volume=3;issue=1;spage=56;epage=62;aulast=López-Gigosos DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.